Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial
- 28 February 2011
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet Neurology
- Vol. 10 (2), 140-147
- https://doi.org/10.1016/s1474-4422(10)70321-5
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trialThe Lancet Neurology, 2010
- Clinical features of spinal and bulbar muscular atrophyBrain, 2009
- Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophyAnnals of Neurology, 2009
- Walking capacity evaluated by the 6‐minute walk test in spinal and bulbar muscular atrophyMuscle & Nerve, 2008
- Natural history of spinal-bulbar muscular atrophyNeurology, 2008
- The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate CancerJournal of Urology, 2008
- Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophyNeuropathology and Applied Neurobiology, 2007
- PERFORMANCE-BASED ASSESSMENT OF FUNCTIONAL LIMITATION AND MUSCLE ENDURANCE: RELIABILITY OF THE ADULT MYOSITIS ASSESSMENT TOOL.Journal of Neurologic Physical Therapy, 2004
- Testosterone Reduction Prevents Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular AtrophyNeuron, 2002
- A Comprehensive Endocrine Description of Kennedy’s Disease Revealing Androgen Insensitivity Linked to CAG Repeat LengthJournal of Clinical Endocrinology & Metabolism, 2002